The cyclopentenone prostaglandin 15-deoxy-Δ 12,14-PGJ2 attenuates the development of colon injury caused by dinitrobenzene sulphonic acid in the rat

被引:88
作者
Cuzzocrea, S
Ianaro, A
Wayman, NS
Mazzon, E
Pisano, B
Dugo, L
Serraino, I
Di Paola, R
Chatterjee, PK
Di Rosa, M
Caputi, AP
Thiemermann, C
机构
[1] Univ Messina, Sch Med, Inst Pharmacol, I-98100 Messina, Italy
[2] Univ Messina, Dept Biomorphol, I-98100 Messina, Italy
[3] St Bartholomews & Royal London Sch Med & Dent, William Harvey Res Inst, Dept Expt Med & Nephrol, London EC1M 6BQ, England
[4] Univ Naples Federico II, Dept Expt Pharmacol, Naples, Italy
关键词
15-deoxy-Delta (12,14)-PGJ(2); PPAR; inflammation; colitis;
D O I
10.1038/sj.bjp.0705077
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 Inflammatory bowel disease (IBD) is characterized by oxidative and nitrosative stress, leukocyte infiltration, and increased expression of the adhesion molecules intercellular adhesion molecule 1 (ICAM-1) in the colon. Recent evidence also suggests that the cyclopentenone prostaglandin (PG) 15-deoxy-Delta(12,14)-PGJ(2) (15d- PGJ(2)) functions as an early anti-inflammatory signal. 2 The aim of the present paper is to investigate the effects of 15d-PGJ(2) in rats subjected to experimental colitis. 3 Colitis was induced in rats by intra-colonic instillation of dinitrobenzene sulphonic acid (DNBS). 15d-PGJ(2) was administered daily as intraperitoneal injection (20 or 40 mug kg(-1)). On day 4, animals were sacrificed and tissues were taken for histological and biochemical analysis. 4 15d-PGJ2 significantly reduced the degree of haemorrhagic diarrhoea and weight loss caused by administration of DNBS. 15d-PGJ(2) also caused a substantial reduction of (i) the degree of colonic injury, (ii) the rise in myeloperoxidase (MPO) activity (mucosa), (iii) the increase in the tissue levels of malondialdehyde (MDA) and (iv) of the pro-inflammatory cytokines tumour necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta). 5 Furthermore, 15d-PGJ(2) reduced the increase in immunohistochemical staining for (i) inducible nitric oxide synthase (iNOS), (ii) nitrotyrosine and (iii) poly (ADP-ribose) polymerase (PARP), as well as (iv) the increased expression of ICAM-I caused by DNBS in the colon. 6 Electrophoresis mobility shift assay (EMSA) of inflamed colon revealed that 15d- PGJ(2) also caused a substantial reduction of the activation of nuclear factor-kappaB (NF-kappaB). Furthermore, 15d-PGJ(2) stimulates the activation of heat shock protein 72 (hsp72) in the inflamed colon, as assessed by Western blot analysis. 7 In conclusion, 15d-PGJ(2) reduces the development of experimental colitis.
引用
收藏
页码:678 / 688
页数:11
相关论文
共 47 条
[1]   SPONTANEOUS INTESTINAL INFLAMMATION AND NITRIC-OXIDE METABOLISM IN HLA-B27 TRANSGENIC RATS [J].
AIKO, S ;
GRISHAM, MB .
GASTROENTEROLOGY, 1995, 109 (01) :142-150
[2]  
Ajuebor MN, 2000, AM J PHYSIOL-GASTR L, V279, pG238
[3]   ANTIPROLIFERATIVE PROSTAGLANDINS ACTIVATE HEAT-SHOCK TRANSCRIPTION FACTOR [J].
AMICI, C ;
SISTONEN, L ;
SANTORO, MG ;
MORIMOTO, RI .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (14) :6227-6231
[4]  
BAUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141
[5]   Oxidative damage and tyrosine nitration from peroxynitrite [J].
Beckman, JS .
CHEMICAL RESEARCH IN TOXICOLOGY, 1996, 9 (05) :836-844
[6]   NITRIC-OXIDE SYNTHASE ACTIVITY IN ULCERATIVE-COLITIS AND CROHNS-DISEASE [J].
BOUGHTONSMITH, NK ;
EVANS, SM ;
HAWKEY, CJ ;
COLE, AT ;
BALSITIS, M ;
WHITTLE, BJR ;
MONCADA, S .
LANCET, 1993, 342 (8867) :338-340
[7]  
Colville-Nash PR, 1998, J IMMUNOL, V161, P978
[8]  
Cuzzocrea S, 1998, IMMUNOLOGY, V93, P96
[9]   Protective effects of 3-aminobenzamide, an inhibitor of poly (ADP-ribose) synthase in a carrageenan-induced model of local inflammation [J].
Cuzzocrea, S ;
Zingarelli, B ;
Gilad, E ;
Hake, P ;
Salzman, AL ;
Szabó, C .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 342 (01) :67-76
[10]   Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor γ (BPARγ) heterodimer:: A basis for new therapeutic strategies [J].
Desreumaux, P ;
Dubuquoy, L ;
Nutten, S ;
Peuchmaur, M ;
Englaro, W ;
Schoonjans, K ;
Derijard, B ;
Desvergne, B ;
Wahli, W ;
Chambon, P ;
Leibowitz, MD ;
Colombel, JF ;
Auwerx, J .
JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 193 (07) :827-838